- Company
- Won-dollar rate lowest in 6mths... industry mixed
- by Kim, Jin-Gu May 23, 2025 05:51am
- With the won-dollar exchange rate falling below KRW 1,400, pharmaceutical and biotech companies are experiencing a mix of anticipation and concern. If the prolonged high exchange rate returns to previous levels, API imports and overseas clinical trial costs are expected to decrease, leading to an improvement in the cost structure. On the othe
- Company
- Will Tibsovo be reimbursed for cholangiocarcinoma this time?
- by Eo, Yun-Ho May 22, 2025 06:10am
- Attention is focused on whether the targeted anticancer drug “Tibsovo” for cholangiocarcinoma and acute myeloid leukemia will be successful in its attempt to be reimbursed by health insurance in Korea. Servier&160;Korea’s IDH1 (isocitrate dehydrogenase 1) genetic mutation targeting therapy recently passed the Health Insurance Review an
- Company
- SK Bioscience wins the '8-year Prevenar patent dispute'
- by Kim, Jin-Gu May 22, 2025 06:09am
- In a patent infringement trial against Pfizer involving SK Bioscience's export of 'SKYPneumo' raw solution, SK Bioscience has won after eight years. The latest ruling is expected to enable SK Bioscience's global export of its pneumococcal conjugate vaccine 'SKYPneumo' raw solution. Ruling that 'Exporting SK Bioscience's SKYPneumo ra
- Company
- KPBMA proposes policies ahead of the presidential election
- by Kim, Jin-Gu May 22, 2025 06:08am
- Ahead of South Korea's 21st presidential election, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has proposed "The Ten Pillars of Pharmaceutical and Biotechnology Policies." KPBMA's proposal can be summarized in three keywords: supporting R&D, establishing an AI-based new drug development platform, and improvi
- Company
- "Aiming the Alzheimer's market with ultrasound"
- by Whang, byung-woo May 22, 2025 06:07am
- Korea's biotech company Deepsonbio is gaining interest for its ultrasound-based brain disorder treatment technology. The company's recent exploratory clinical trials demonstrated the effect of improving cognitive function for patients with Alzheimer's disease and those with normal pressure hydrocephalus. Deepsonbio plans to enter the market
- Company
- Dyslipidemia drug 'Leqvio' enters drug price negotiatiation
- by Eo, Yun-Ho May 21, 2025 06:37am
- Leqvio, a new drug for dyslipidemia administered once yearly, has recently entered into negotiations with the National Health Insurance Service (NHIS). In February, Novartis Korea's siRNA drug Leqvio (inclisiran) had initially failed at setting criteria for 'reducing cardiovascular events in patients with atherosclerotic cardiovascular d
- Company
- ‘Bispecific antibodies gain attention as option for DLBCL'
- by Whang, byung-woo May 21, 2025 06:36am
- Diffuse large B-cell lymphoma (DLBCL) is considered a difficult disease to treat due to its aggressive nature, but the emergence of new drugs has brought about a paradigm shift in its treatment. As efforts for DLBCL progress towards a cure beyond extending survival, the role of bispecific antibody therapies is garnering attention. Georg Le
- Company
- Trodelvy may be the 1st drug reimbursed with ICER benefits
- by Eo, Yun-Ho May 21, 2025 06:36am
- ADC breast cancer drug Trodelvy may soon be listed for insurance reimbursement in Korea. Gilead Sciences recently finalized price negotiations with the National Health Insurance Service for its triple-negative breast cancer (TNBC) treatment Trodelvy (sacituzumab govitecan). As a result, Trodelvy is scheduled to be presented at the Heal
- Company
- MSD expands domestic clinical trial cooperation
- by Whang, byung-woo May 20, 2025 06:00am
- MSD Korea has broken its record for the most clinical trial approvals in Korea and is now in full swing, developing innovative new drugs for Koreans. With open innovation playing an increasingly important role in new drug research and development (R&D), MSD is expanding its ties with Korea, which plays a pivotal role in its global clinical tr
- Company
- Hanmi-MSD collaborate for R&D
- by Cha, Jihyun May 20, 2025 05:59am
- Hanmi Pharmaceutical entered into a clinical trial collaboration agreement with the U.S.-based Merck (MSD) for developing an immune anticancer drug candidate. The clinical collaboration between Hanmi Pharmaceutical (hereafter, Hanmi) and Merck has expanded to three cases. In addition to clinical trial collaboration, Hanmi continues to collaborat
